1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Tibet Weixinkang Medicine Co., Ltd.

Tibet Weixinkang Medicine Co., Ltd.

603676.SS
Tibet Weixinkang Medicine Co., Ltd.CN flagShanghai Stock Exchange
8.90
CNY
-0.11
- -
3.87BMarket Cap
Tibet Weixinkang Medicine Co., Ltd.
603676.SS
(Shanghai Stock Exchange)

Recent

price

8.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
- -
2.42
1.19
1.08
1.73
1.73
1.71
2.48
3.24
3.09
3.01
2.63
2.96
Revenue per Share
- -
- -
0.62
0.32
0.26
0.17
0.13
0.14
0.23
0.41
0.5
0.57
0.54
0.63
Basic EPS, GAAP
- -
- -
0.39
0.22
-0.04
-0.03
0.15
0.19
0.28
0.39
0.4
0.73
0.24
-0.16
Free Cash Flow per Basic Share
- -
- -
- -
0.16
0.01
0.08
0.05
0.05
0.1
0.16
0.23
0.41
0.38
0.53
Dividend per Share
- -
- -
1.95
1.14
1.46
1.41
1.5
1.63
1.78
1.92
2.19
2.25
2.43
2.55
Book Value per Share
- -
- -
2.06
1.19
2.09
1.98
2.06
2.2
2.36
2.68
3
3.14
3.34
3.45
Tangible Book Value per Share
- -
- -
182
359
391
432
428
417
417
432
428
432
431
423
Basic Weighted Avg Shares
342
391
440
426
420
746
741
716
1,034
1,399
1,323
1,300
1,136
1,253
Sales/Revenue/Turnover
29.31
32.12
27.33
26.14
20.17
7.47
6.04
6.33
9.42
11.95
11
21.73
22.83
26.84
Operating Margin (%)
7
9
12
19
19
23
27
31
34
41
49
53
51
- -
Depreciation Expense
83
107
113
115
102
73
56
58
96
177
214
246
233
265
Net Income, GAAP
19.44
15.23
10.41
9.43
11.98
5.54
15.55
16.08
16.04
2.96
0.84
11
17.89
12.31
Effective Tax Rate (%)
24.23
27.31
25.65
26.95
24.17
9.84
7.51
8.16
9.28
12.65
16.18
18.93
20.5
21.19
Profit Margin (%)
100
69
132
175
526
513
533
524
590
727
805
888
941
992
Working Capital
- -
- -
- -
- -
- -
- -
- -
4
2
3
4
2
7
1
LT Debt
248
286
403
459
858
898
930
983
1,067
1,221
1,340
1,385
1,476
1,490
Total Equity
- -
37.31
29.91
22.96
11.3
5.92
4.08
3.97
7.93
14.06
11.17
18.36
14.75
20.19
Return on Invested Capital (%)
- -
42.43
37.66
30.08
20.17
12.24
8.71
8.79
13.38
22.4
24.11
25.64
22.88
25.7
Return on Capital (%)
- -
47.82
37.69
30.13
20.73
12.43
8.9
8.83
13.47
22.53
24.25
25.79
23.05
25.86
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
3
2
2
LT Borrowings
- -
- -
- -
LT Finance Leases
2
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
435
435
435
Market Capitalization
4,293
4,151
4,282

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,315
1,365
1,341
Cash, Cash Equivalents & STI
1,019
1,052
1,029
Accounts Receivable, Net
172
166
158
Inventories
42
44
48
Total Current Liabilities
427
388
349
Payables & Accruals
- -
- -
- -
ST Debt
3
2
2
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.74%
8.53%
6.56%
Free Cash Flow
-64.89%
21.91%
-67.7%
Net Income, GAAP
12.24%
35.84%
-5.41%
Sales/Revenue/Turnover
12.88%
11.99%
-12.65%
Total Cash Common Dividend
- -
59.63%
-8.1%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
318
315
361
306
1,300
2025
296
290
273
- -
1,136
2026
322
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.22
- -
- -
- -
0.57
2025
0.2
- -
- -
- -
0.54
2026
0.16
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.41
2025
0.01
- -
- -
- -
0.38
2026
- -
- -
- -
- -
- -
Similar Companies
Bausch Health Companies Inc. (BHC.TO)
Guardion Health Sciences, Inc. (GHSI)
Lotus Ventures Inc. (LTTSF)
Vivesto AB (VIVE.ST)
China Animal Husbandry Industry Co., Ltd. (600195.SS)
Ajanta Pharma Limited (AJANTPHARM.NS)
Business
Tibet Weixinkang Medicine Co., Ltd. engages in the research, development, production, and sale of chemical pharmaceutical preparations and their active pharmaceutical ingredients in China. The company specializes in parenteral nutrition and related products, including multivitamins for injection (12), pediatric multivitamin injection (13), multi-trace element injection, compound electrolyte injection (V), mixed sugar electrolyte injections, potassium magnesium aspartate injection, potassium aspartate injection, iron sucrose injection, injectable acetylcysteine solution for inhalation, compound amino acid injections, antibiotics, and medicines for digestive system and liver diseases; it also provides pharmaceutical marketing services. Founded in 2006 and headquartered in Lhasa, Tibet Autonomous Region, the company operates primarily in the domestic market through a network covering over 3,000 secondary and above-level medical institutions, with 11 to 13 subsidiaries in locations including Beijing, Inner Mongolia, Hainan, Jiangsu, and Hong Kong. Tibet Weixinkang Medicine Co., Ltd., formerly known as Weixinkang Medicine Youxian Gongsi, changed its name in 2015 and listed on the Shanghai Stock Exchange mainboard (603676.SS) in 2017. In recent developments, the company announced a share repurchase program in 2024 for up to CNY 30 million at a price not exceeding CNY 12.12 per share; it received market approval for dopamine hydrochloride injection to treat shock syndromes; and participated in the 89th National Drug Transaction Fair in Wuhan in November 2024, showcasing key parenteral nutrition products amid ongoing R&D expansion with over 40 projects in development, 15 invention patents, and 17 new drug certificates obtained since 2015.